Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Aptamer Engineering of Lentiviral Vectors for Cardiac Gene Therapies - Project Summary/abstract Overview: Hypertrophic Cardiomyopathy Is the Leading Cause of Sudden Death in Young Individuals, Where Several Loss-of-function Mutations in Key Sarcomeric Proteins Cause Hypertrophy. Gene Therapy Approaches That Drive the Overexpression of the Correct Genes Can Be Used to Remodel the Heart Tissue and Restore Function. However, No Gene Therapies Have Been Developed for in Vivo Targeting of the Heart to Date. a Key Bottleneck in the Field Is the Ability to Engineer Advanced Viral Vectors With Prescribed Tropism in the Patient’s Body. Lentiviral Vector (LVV) Engineering Applies Rational Design Principles to Define Components of the Vector Envelope, Such as Attachment Proteins, Leading to Vectors With Programmable Tissue Specificity and Off-target Activity.
Committed
$289,665
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…